New drug aims to free MDS patients from frequent blood transfusions
NCT ID NCT05181592
Summary
This study is testing a drug called luspatercept to see if it can help patients with a specific type of lower-risk myelodysplastic syndrome (MDS) who have anemia and require regular blood transfusions. The main goal is to see if the treatment can allow patients to go at least 8 weeks without needing a transfusion. About 70 patients in several European countries will receive the drug and be monitored for its effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica di Ematologia Istituto oncologico della Svizzera Italiana
Bellinzona, 6500, Switzerland
-
Hospital General Universitario Gregorio Marañón
Madrid, 28009, Spain
-
Hospital Universitario Central de Asturias
Oviedo, 33011, Spain
-
Hospital Universitario y Politecnico La Fe de Valencia
Valencia, 46026, Spain
-
Hospital Vall d´Hebron
Barcelona, 08023, Spain
-
Institut Català d' Oncologia de Badalona
Badalona, 8916, Spain
-
Klinikum rechts der Isar
München, 81675, Germany
-
Medizinische Universität Innsbruck
Innsbruck, 6020, Austria
-
Medizinische Universität Wien
Vienna, 1090, Austria
-
University Hospital of Salamanca
Salamanca, 37007, Spain
-
Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor
Bern, 3010, Switzerland
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitätsspital Basel
Basel, 4031, Switzerland
Conditions
Explore the condition pages connected to this study.